Founding father recognised for outstanding cancer care
15 November 2017
A founding father of Melanoma Institute Australia, Professor William McCarthy AM, has been recognised for his contributions to cancer care by being awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care at the Clinical Oncology Society of Australia dinner last night.
The award is given annually to a national leader who has made a significant contribution over a long period of time to cancer care through research, clinical leadership and community service.
One nominee wrote: “There is no questioning Professor McCarthy’s contribution to the improvement of the care of patients with cancer and in particular patients with melanoma in his home state of New South Wales, in Australia and internationally…. in the roles of clinician, researcher, teacher and contributor to national forums related to the disease.”
The former Executive Director of the Sydney Melanoma Unit (now known as Melanoma Institute Australia) has led the world in melanoma education, general medical education and melanoma surgery.
Professor McCarthy graduated from The University of Sydney’s Faculty of Medicine in 1958 and trained in surgery at St Vincent’s Hospital Sydney. He then obtained a Master’s Degree in Medical Education at the University of Illinois, Chicago, and worked in various surgical registrar postings in the United Kingdom.
Returning to Sydney in 1968, Professor McCarthy was appointed a Lecturer in Surgery at The University of Sydney and a Visiting Medical Officer at Sydney Hospital where he worked with Professor Gerry Milton in the Sydney Melanoma Unit.
His academic achievements include some 180 peer‐reviewed publications over a span of 50 years. He was promoted steadily in the University, becoming Professor of Surgery (Melanoma and Skin Oncology) in 1990; a post he held until his retirement in 2005 when he was appointed Professor Emeritus.
His contributions were recognised by appointment as a Member (AM) of the Order of Australia in 1993 and receipt of the World Health Organisation Melanoma Award in 2001. He served on the Clinical Oncology Society of Australia Council and was President in 1992 and 1993.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.